<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142085">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251276</url>
  </required_header>
  <id_info>
    <org_study_id>V232-059-10</org_study_id>
    <secondary_id>rHB01C</secondary_id>
    <nct_id>NCT01251276</nct_id>
  </id_info>
  <brief_title>Hepatitis B Challenge Dose in Adults</brief_title>
  <official_title>A Study to Estimate the Immune Response Following a Challenge Dose in Adults (≥50 Years Old) Vaccinated With a Primary Series of an Hepatitis B Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      =&gt; To describe the Seroprotection rate (SPR) at least 2 years following completion of a
      primary series with an Hepatitis B vaccine and 1 month following a challenge dose of
      HBVaxPro.

      Secondary Objective:

      =&gt; To describe the safety and tolerability of a challenge dose of HBVaxPro in adults ≥50
      years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-challenge anti HBs seroprotection rate (percentage of subjects with titre &gt;=10 mIU/mL)</measure>
    <time_frame>Day 1 (Day of vaccination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-challenge anti HBs seroprotection rate (percentage of subjects with titre &gt;=10 mIU/mL)</measure>
    <time_frame>1 month post challenge dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Injection-site reactions, systemic injection site reactions, adverse events and serious adverse events</measure>
    <time_frame>Day 1 to Day 30 post challenge dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>HBVaxPro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1 dose at Day 1</intervention_name>
    <description>1 dose 10μg/mL (1mL)</description>
    <arm_group_label>HBVaxPro</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In general good health based on a medical history.

          -  Received 3 doses of an Hepatitis B vaccine at least 2 years prior to enrollment in
             this study.

        Exclusion Criteria:

          -  Known history of previous Hepatitis B infection.

          -  History of vaccination with any Hepatitis B vaccine within the last 2 years.

          -  History of febrile illness.

          -  Known or suspected hypersensitivity to any component of HBVaxPro.

          -  Receipt of medication / vaccine that may interfere with study assessments.

          -  Known or suspected immune impairment.

          -  Pregnant women and nursing mothers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Wehrlen-Grandjean, MD</last_name>
    <role>Study Director</role>
    <affiliation>MCM Vaccines B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Halifax</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Pointe Claire</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Surrey</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Truro</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Arhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Addlestone, Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Bexhill on Sea, East Sussex</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Blackpool, Lancashire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Bradford Upon Avon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Yaxley, Peterborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 14, 2017</lastchanged_date>
  <firstreceived_date>November 23, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
